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Introduction: According to some studies, ascorbic acid possesses antiviral properties. These studies were mainly
focused on the common cold, with very few focusing on other viral infections.
Case presentation: We report the case of a 54-year-old Caucasian woman with chronic arthralgia due to persistent
parvovirus B19 viremia. High doses of ascorbic acid treatment were initiated due to the failure of conventional
analgesic therapy. Clinical benefit was observed with a simultaneous loss of biological parvovirus B19 viremia.
Conclusions: This observation shows a potential benefit of the use of ascorbic acid against parvovirus B19
infections, even if this case is not sufficient to draw any definite conclusions.
Keywords: Ascorbic acid, Parvovirus B19, Arthralgia, ChronicIntroduction
Most immunocompetent people with detectable specific
human parvovirus B19 (pvB19) antibodies do not recall
ever having had any specific symptoms. Arthritis and arth-
ralgia during acute pvB19 infection are more commonly
observed in adults rather than children. The symptoms
typically subside in weeks, although the arthropathy may
persist for months in 20% of affected women [1]. Thera-
peutic options for pvB19 chronic arthralgia are limited.
Since it was isolated in the 1930s, ascorbic acid has been
proposed for treating viral infections. It became particu-
larly popular in the 1970s when Nobel laureate Linus
Pauling’s trials concluded that ascorbic acid could prevent
and alleviate the common cold, but these results are still
debated [2]. The safety of high doses of ascorbic acid is
now well proved, especially by recent work on cancer
treatment with high-dose injections over a medium-term
duration [3]. The efficacy is fickle for the common cold,
probably because high doses are necessary [2]. However,
high doses of ascorbic acid seem effective against infec-
tious mononucleosis and shingles [4,5].* Correspondence: philippe.brouqui@univ-amu.fr
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We report the case of a 54-year-old Caucasian woman
with no relevant past medical history who presented at an
outpatient clinic with unexplained isolated joint pain that
had been ongoing for six months. No arthritis, rash, fever
or anemia symptoms had been reported at the beginning
or during the course of disease. During her physical exam-
ination, wrist, elbow, shoulder and knee pain was rated by
a visual analog scale (VAS) at 60 out of 100. An initial
five-day course of corticosteroid therapy (prednisone, 20
milligrams per day) was initiated by her general practi-
tioner with clinical improvement, but relapse was ob-
served at the end of treatment. A dose of acetaminophen
(four to six grams per day) was then prescribed for three
weeks, unsuccessfully (VAS=50 out of 100). Finally, a non-
steroidal-anti-inflammatory drug ketoprofen was given at
200 milligrams per day for four months, with a moderate
efficacy (VAS=30 out of 100) before she was referred to us
for medical advice.
Among the tests performed for etiological investiga-
tions, high levels of pvB19 immunoglobulin G (IgG) and
immunoglobulin M (IgM) were found in her serum and
her PCR was positive for six months after the onset of
symptoms. Her pvB19 blood serology and PCR were still
positive at 11 and 13 months after the onset of symptoms
(see Table 1). Her rheumatoid factor, antinuclear, anti-
transglutaminase and anti-endomysium immunoglobulin
A (IgA) antibodies, as well as anti-gliadin IgG and IgAral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient biological and clinical evolution during medical follow-up
Date 20 August 2013 22 October 2013 11 November 2013 31 December 2013a 21 January 2014 30 January 2014b 06 March 2014
Month after symptoms onset 6 8 10 10 11 11 13
pvB19-PCRc + + + + − − −
pvB19-PCRd CT 32 34 38 39 − − −
pvB19-serology IgMe + + + + + + +
pvB19-IgM positivity ratio 6.1 6 6.77 6.7 6.5 NA 5.9
pvB19-serology IgGf + + + + + + +
pvB19-IgG positivity ratio 5.3 4.6 4.4 3.4 3.4 NA 3.8
Analgesic Ketoprofen Ketoprofen Ketoprofen Ketoprofen None None None
Visual analog scale (/100) 30 30 30 30 5 40 10
All biological analyses were performed on serum (defibrinated plasma).
aFirst ascorbic acid treatment.
bSecond ascorbic acid treatment.
cParvovirus B 19 polymerase chain reaction.
dParvovirus B 19 polymerase chain reaction cycle threshold.
eImmunoglobulin M.
fImmunoglubulin G.
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Because of persistent circulating pvB19-DNA and poor
treatment response, we decided to stop the treatment and
to begin oral acid ascorbic at 10 grams per day for 10 days,
as suggested in other viral illnesses. At five days after the
initiation of treatment, she described an important de-
crease in symptoms (VAS=5). At three weeks after treat-
ment, a pvB19-PCR analysis on her serum was negative
for NS1 protein encoding gene, while her serology was
still positive for IgG and IgM. A relapse occurred three
weeks after the end of treatment, but she fully recovered
after a second administration of the same dose for three
complementary weeks. At the time of this report, she re-
mains completely recovered.
Discussion
Few prior studies have reported on the treatment of persist-
ent isolated joint pains due to pvB19 infection. In cases of
acute arthropathy, non-steroidal anti-inflammatory drugs
may exert beneficial effects and are often recommended in
reviews [6-8], but no therapeutic trial has explored the spe-
cific association of pvB19 chronic arthropathy and non-
steroidal anti-inflammatory drug efficiency. Intravenous
immunoglobulin therapy has been tested in severe arthritis
associated with pvB19 infection, with good results in non-
isolated arthropathy [9-14], but non-contributive results in
the case of isolated severe chronic arthropathy [15-17].
While chloroquine has a wide antiviral activity, in vitro
experiments on 4-aminoquinoline drugs and their metabo-
lites suggest that they exacerbate pvB19-associated anemia
by promoting replication [18]. While there is no data
in vitro or in vivo in the literature on the efficacy of ascor-
bic acid on pvB19, the safety of high-dose ascorbic acid
relative to the potential benefit justifies the prescription of
this therapy.
Conclusions
Whilst we are aware that the negativity of the pvB19-PCR
analysis and the clinical improvement of our patient may
be independent and coincidental, we suggest a possible effi-
cacy when high doses of ascorbic acid are used for treating
persistent pvB19 infections. Considering the limited thera-
peutic options for chronic pvB19-associated joint pain and
the lack of side effects associated with ascorbic acid treat-
ment, we suggest using the latter when other therapies have
failed.
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